FDA Approves Pavblu (aflibercept) for Neovascular AMD, RVO, DME, and DR
FDA approves Pavblu to treat several eye conditions that cause vision loss.
The FDA approved Pavblu (aflibercept) for neovascular AMD, macular edema following RVO, DME, and DR. It is a VEGF inhibitor administered by …
The FDA approved Pavblu (aflibercept) for wet age-related macular degeneration, macular edema, diabetic macular edema, and diabetic retinopa…
Systematic review and meta-analysis shows aflibercept biosimilars match reference drug efficacy and safety in AMD and DME
Aflibercept biosimilars match the original drug for eye disease treatment
This systematic review and meta-analysis evaluated aflibercept biosimilars versus reference aflibercept for neovascular age-related macular …
A large review of 4064 patients found that aflibercept biosimilars work just as well as the original drug for two common eye conditions.
AI-based fluid volume quantification predicts visual acuity in neovascular AMD better than CST
AI fluid measurements better predict vision loss than thickness in AMD
This randomized phase III trial in 290 eyes with neovascular AMD found that AI-based quantification of intraretinal and subretinal fluid vol…
AI-based fluid volume tracking explains more vision changes than standard thickness measurements in macular degeneration patients.
Systematic review finds radiotherapy combined with anti-VEGF therapy increases risk of vision loss compared to anti-VEGF monotherapy in nAMD
Radiotherapy plus anti-VEGF therapy increases vision loss risk for nAMD
This systematic review and meta-analysis evaluated radiotherapy combined with anti-VEGF therapy versus anti-VEGF monotherapy for neovascular…
Adding radiotherapy to anti-VEGF treatment for wet macular degeneration was linked to a higher risk of vision loss compared to anti-VEGF alo…
Proteomic profiling in anti-VEGF-treated AMD patients reveals VEGF-independent immune pathway activation
Why Immune Cells Keep Damaging Your Eyes
This observational study analyzed vitreous proteomic profiles in eight patients with neovascular AMD receiving anti-VEGF therapy compared to…
Standard eye drops for AMD stop one problem, but a second, hidden immune attack is still hurting your vision.
FDA Approves Eylea HD (aflibercept) for nAMD, DME, Diabetic Retinopathy, and Macular Edema Following RVO
FDA approves a new, higher-dose version of the eye medicine Eylea
The FDA has approved Eylea HD, a VEGF inhibitor, for the treatment of neovascular age-related macular degeneration, diabetic macular edema, …
FDA approves higher-dose Eylea to treat four eye conditions that damage the retina and threaten vision, potentially reducing how often patie…
Subretinal fibrosis develops in 40-50% of nAMD eyes after 5 years of anti-VEGF therapy, associated with worse vision
How often does scarring develop in treated macular degeneration eyes?
A systematic review and meta-analysis of 58 studies in anti-VEGF-treated nAMD eyes found subretinal fibrosis developed in approximately 10-1…
Scarring in treated macular degeneration eyes affects 10% to 15% within two years and up to half by five years, causing vision loss averagin…
FDA Approves Byooviz (ranibizumab) for Neovascular AMD, Macular Edema Following RVO, and Myopic CNV
FDA approves a new eye medicine called Byooviz for three conditions that can cause vision loss
The FDA has approved Byooviz, a VEGF inhibitor, for intravitreal injection to treat neovascular age-related macular degeneration, macular ed…
FDA approves Byooviz to treat three eye conditions causing vision loss from leaky blood vessels in the retina.
Meta-analysis: Anti-VEGF biosimilars show equivalent efficacy, safety to reference agents in nAMD
Can cheaper eye drugs work as well as expensive ones? A major review says yes for vision loss in older adults
A meta-analysis of 17 RCTs (n=6694) found no clinically meaningful differences in BCVA improvement at 12 weeks (MD=-0.42, p=0.17) or endpoin…
Cheaper eye drug copies work just as well as expensive originals for treating vision loss in older adults, a major review confirms.
Research across Age-Related Macular Degeneration
Related studies from across the Age-Related Macular Degeneration family.
Obstructive Sleep Apnea Associated with Higher Odds of Age-Related Macular Degeneration
Large study links obstructive sleep apnea to higher risk of age-related macular degeneration
A systematic review and meta-analysis of 3,536,314 adults found that obstructive sleep apnea (OSA) was associated with higher odds of age-re…
A massive analysis of over 3.5 million people suggests obstructive sleep apnea is linked to a higher risk of age-related macular degeneratio…
Systematic review and meta-analysis finds no significant association between diabetic retinopathy and age-related macular degeneration
Diabetic retinopathy and age-related macular degeneration show no significant link
This systematic review and meta-analysis evaluates the association between diabetic retinopathy and age-related macular degeneration.
A meta-analysis found no significant relationship between diabetic retinopathy and age-related macular degeneration, though existing data ha…
Avacincaptad pegol reduces geographic atrophy growth compared to sham in Age-Related Macular Degeneration patients
This Eye Injection Slows Blindness for Two Years Straight
This phase 3, randomized, sham-controlled study evaluated avacincaptad pegol in patients with non-center point-involving geographic atrophy.
For patients with a leading cause of blindness, this treatment offers lasting protection without new side effects.
Narrative review associates melatonin use with delayed age-related macular degeneration in Americans over 40
Melatonin May Slow Vision Loss in Aging Eyes
This narrative review examines the association between melatonin use and delayed age-related macular degeneration (AMD) in Americans over th…
Melatonin, the sleep hormone, may slow vision loss in aging eyes by fighting the oxidative stress that damages cells in age-related macular …
Smoking, aging, and CRP levels associated with cataract and AMD comorbidity risk in 640 participants
Study links smoking and aging to higher risk of cataract and macular degeneration
This retrospective case-control study evaluated risk factors for cataract and age-related macular degeneration comorbidity in 640 participan…
Smoking combined with aging exponentially raises the risk of developing both cataracts and macular degeneration in people over 75.
Retrospective study links systemic BP control to better visual outcomes with conbercept for RVO-related macular edema
Your Blood Pressure May Decide How Well Eye Injections Work
A retrospective cohort study of 76 hypertensive patients with macular edema secondary to retinal vein occlusion found that those with contro…
If you need eye injections for fluid swelling behind the retina, keeping your blood pressure in check could decide how much vision you get b…
Retrospective study identifies imaging biomarkers for AMD progression using machine learning models
Can an eye scan predict who will lose central vision from macular degeneration?
A retrospective cohort study of 324 AMD patients developed machine learning models to predict progression from early to late AMD over 3 year…
Eye scans showing pigment changes and drusen deposits can predict which patients with early macular degeneration are most likely to lose cen…
Stanford OCT AMD classification shows excellent intergrader agreement in diagnostic development study
Can a new eye scan system help doctors agree on macular degeneration stages?
A diagnostic classification development study of 108 patients assessed the newly proposed Stanford OCT Based AMD Classification (SOAC).
A new eye scan system helps specialists agree on macular degeneration stages, reducing confusion for patients and creating a shared language…
Intravitreal Anti-VEGF Shows Anatomic and Visual Gains in Irvine-Gass Syndrome Meta-Analysis
Can eye injections help people with Irvine-Gass syndrome see better?
A systematic review and meta-analysis of 343 eyes with Irvine-Gass syndrome found intravitreal anti-VEGF treatment was associated with a mea…
Eye injections for Irvine-Gass syndrome reduced swelling and improved vision in most patients, though doctors still need to prove these trea…
Questions about Neovascular Age-Related Macular Degeneration
What happens to my immune system when I get anti-VEGF injections for AMD?
Anti-VEGF injections for AMD block abnormal blood vessel growth but may also activate immune pathways, including T-cell and inflammatory signals, which could affect long-term outcomes.
Full answer →Can the FDA-approved drug Eylea HD be used to treat my neovascular AMD?
Yes, Eylea HD (aflibercept) is FDA-approved to treat neovascular (wet) age-related macular degeneration (nAMD).
Full answer →Does combining radiotherapy with anti-VEGF therapy increase my risk of losing vision?
Yes, combining radiotherapy with anti-VEGF therapy increases the risk of vision loss compared to anti-VEGF alone, based on systematic reviews.
Full answer →Are aflibercept biosimilars just as safe and effective as the original drug for AMD?
Yes, aflibercept biosimilars are as safe and effective as the original drug for neovascular AMD, based on a meta-analysis of 11 studies.
Full answer →Does the FDA approval of Pavblu mean it can treat my neovascular AMD?
Yes, Pavblu (aflibercept) is FDA-approved specifically for neovascular AMD, so it can treat your condition.
Full answer →